Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Beam Therapy vs IMRT for Esophageal Cancer
NCT03801876Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2019
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in esophageal cancer (2 arms), sponsored by NRG Oncology. Primary endpoints: Overall survival at 4 years and Incidence of specific grade 3+ cardiopulmonary adverse events at 8 years. Started Jun 2019; status: active, not recruiting.
02
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03801876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801876.